ArticleCancer cell international2025
Hsa-miR-423-5p selectively loaded in hypoxic exosomes reduces the sensitivity of normoxic hepatocellular carcinoma to sorafenib via autophagy.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundFor patients with advanced hepatocellular carcinoma, sorafenib is considered a highly effective targeted molecular drug; however, sorafenib resistance limits its therapeutic efficacy. Hepatocellular carcinoma, a type of solid tumour, contains hypoxic and oxygen-rich regions within its internal structure. This study investigated the mechanism by which hypoxic hepatocellular carcinoma cells influence the sorafenib sensitivity of normoxic hepatocellular carcinoma cells through the secretion of hypoxic exosomes containing miRNA signals.
methodsExperiments like CCK-8, IC50, and flow cytometry were used to determine how hypoxic exosomes affect the sorafenib sensitivity of normoxic hepatocellular carcinoma cells. A high-throughput sequencing approach was employed to identify the target of miR-423-5p selectively loaded in hypoxic exosomes. Subsequently, RNA pull-down, RIP, and other experiments were conducted to investigate the mechanism by which hsa-miR-423-5p is selectively loaded into hypoxic exosomes through the RNA-binding proteins (RBPs) acting upstream. Next, Western blot, quantitative real-time PCR, apoptosis flow cytometry, and dual-luciferase reporter assays were performed to investigate how hsa-miR-423-5p affects downstream direct targets and modulates the sorafenib sensitivity of normoxic hepatocellular carcinoma cells through an autophagy mechanism. Finally, the experimental results were validated in an orthotopic hepatocellular carcinoma mouse model by constructing lipid nanoparticles (LNPs) that carry hsa-miR-423-5p inhibitors.
resultsHypoxic hepatocellular carcinoma cells secreted hypoxic exosomes, which could be taken up by normoxic hepatocellular carcinoma cells. These exosomes subsequently reduced the sorafenib sensitivity of normoxic hepatocellular carcinoma cells through an autophagy mechanism. High-throughput sequencing revealed that hsa-miR-423-5p was selectively loaded into hypoxic exosomes via HNRNPA1. In normoxic hepatocellular carcinoma cells, hsa-miR-423-5p promoted autophagy by targeting the downstream target TAB2, thereby decreasing the sorafenib sensitivity of normoxic hepatocellular carcinoma cells to sorafenib.
conclusionsIn response to the upstream factor HNRNPA1, hsa-miR-423-5p is selectively loaded into hypoxic exosomes, which then target the downstream protein TAB2 to regulate the autophagy pathway and reduce the sorafenib sensitivity of normoxic hepatocellular carcinoma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.